Urinary Urgency Incontinence Clinical Trial
Official title:
Clinical Study of Neuspera's Implantable Sacral Nerve Stimulation (SNS) System in Patients With Symptoms of Urinary Urgency Incontinence (UUI)
| Verified date | March 2024 |
| Source | Neuspera Medical, Inc. |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
Prospective, multi-center, single-arm, seamless phase-pivotal study conducted in participants diagnosed with UUI who have failed or could not tolerate more conservative treatment. The trial will be conducted in two phases. Objective of Phase I: To assess the utilization of the system during the Sacral Nerve Stimulation (SNS) trial period and to help inform the length of hours of daily stimulation to be used in Phase II of the trial. Objective of Phase II: To assess the safety and efficacy of the Neuspera SNS System at 6-months for the primary efficacy endpoint and at 12 months for secondary safety and efficacy endpoints.
| Status | Active, not recruiting |
| Enrollment | 242 |
| Est. completion date | December 2026 |
| Est. primary completion date | July 2024 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 22 Years and older |
| Eligibility | Inclusion Criteria: 1. Has a Body Mass Index (BMI) between 18 and 40. 2. Has a diagnosis of UUI for greater than or equal to 6 months prior to the screening baseline visit date. 3. Has failed or was not a candidate for more conservative treatment (e.g. pelvic floor training, biofeedback, behavioral modification). 4. Has failed or could not tolerate (stopped taking medication due to lack of efficacy or intolerable side effects) or not a good candidate for (as determined by treating physician) at least one (1) antimuscarinic or ß3 adrenoceptor agonist medication. 5. Has a diagnosis of UUI with at least 4 UUI episodes on a 72-hour diary, and minimum of one (1) UUI episode per 24-hour period. Exclusion Criteria: 1. Has a hemoglobin A1c of greater than 8 percent, or has diabetes mellitus with glucosuria. 2. Has diabetic neuropathy. 3. Has interstitial cystitis or bladder pain syndrome as defined by either American Urological Association (AUA) or European Association of Urology (EAU) guidelines, chronic pelvic pain or recurrent symptomatic urinary tract infections. 4. Has neurogenic bladder dysfunction such as traumatic or atraumatic myelopathy, multiple sclerosis, Parkinsonism, or history of cerebrovascular accident. 5. Has documented urinary retention within 6 months prior to the screening baseline visit date. 6. Has clinically significant bladder outlet obstruction. 7. Is a subject with a mechanical obstruction such as benign prostatic hypertrophy, urethral stricture or cancer. 8. Has primary stress incontinence or mixed incontinence where the stress component predominates or has been treated surgically for stress urinary incontinence within 6 months prior to the screening baseline visit date. 9. Has received tibial nerve stimulation (TNS) in the past 3 months for the treatment of overactive bladder or unwilling to stay off TNS therapy for 12-month period following implant. |
| Country | Name | City | State |
|---|---|---|---|
| Belgium | Universiteit Antwerpen | Antwerp | |
| Netherlands | Maastricht University Medical Center | Maastricht | |
| Netherlands | Erasmus University Medical Center | Rotterdam | |
| United States | Midtown Urology | Atlanta | Georgia |
| United States | Urology Austin | Austin | Texas |
| United States | MetroHealth | Cleveland | Ohio |
| United States | Urology Clinics of North Texas (Dallas Center for Pelvic Medicine) | Dallas | Texas |
| United States | Genesis Healthcare Partners | Encinitas | California |
| United States | Women's Health Advantage | Fort Wayne | Indiana |
| United States | Indiana University School of Medicine | Indianapolis | Indiana |
| United States | University of Kansas Hospital | Kansas City | Kansas |
| United States | Comprehensive Urologic Care | Lake Barrington | Illinois |
| United States | UofL Health System (University of Louisville) | Louisville | Kentucky |
| United States | Southern shores urogynecology | Myrtle Beach | South Carolina |
| United States | Ochsner Medical | New Orleans | Louisiana |
| United States | The Institute for Female Pelvic Medicine and Reconstructive Surgery | North Wales | Pennsylvania |
| United States | Adult & Pediatric Urology P.C. | Omaha | Nebraska |
| United States | Clinical Research Center of Florida | Pompano Beach | Florida |
| United States | The Oregon Clinic Urogynecology West | Portland | Oregon |
| United States | Premier Medical Group | Poughkeepsie | New York |
| United States | Specialty Research of St. Louis | Saint Louis | Missouri |
| United States | Kaiser Permanente | San Diego | California |
| United States | University of Washington | Seattle | Washington |
| United States | Virginia Mason | Seattle | Washington |
| United States | Associated Medical Professionals of NY | Syracuse | New York |
| United States | Florida Urology Partners, LLC | Tampa | Florida |
| United States | Southern Urogynecology | West Columbia | South Carolina |
| United States | Minnesota Urology | Woodbury | Minnesota |
| United States | University of Michigan Health - West | Wyoming | Michigan |
| Lead Sponsor | Collaborator |
|---|---|
| Neuspera Medical, Inc. |
United States, Belgium, Netherlands,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Phase II Primary Efficacy Endpoint: Defined as the percentage of participants who experience a 50 percent or more change in Urinary Urgency Incontinence episodes. | Change in Urinary Urgency Incontinence episodes at six months post-completion of the trial phase, relative to the number of Urinary Urgency Incontinence episodes at baseline prior to the trial phase. | Six months | |
| Primary | Phase II Primary Safety Endpoint: Defined as the incidence of device-related serious adverse events in the post-trial period follow-up. | The number of serious adverse events related to the device. | Six months | |
| Secondary | Phase II Change in Quality of Life: Measured from baseline as measured and assessed by the total and subset International Consultation on Incontinence Questionnaire Overactive Bladder Quality of Life score. | Total score (25 min,160 max) with higher score indicating increase impact on quality of life. | 6 and 12 months | |
| Secondary | Phase II Efficacy Endpoint: Defined as the percentage of participants who experience a 50 percent or more change in Urinary Urgency Incontinence. | Change in Urinary Urgency Incontinence episodes at 12 months post-completion of the trial phase, relative to the number of Urinary Urgency Incontinence episodes at baseline prior to the trial phase. | 12 months | |
| Secondary | Phase II Urgent Voids per Day | Change in urgent voids per day from baseline to 6-months and 12 months. Calculated across all diary episodes with at least mild urgency. | 6 and 12 months | |
| Secondary | Phase !! Change in Average Number of Daily Voids | Change in average number of daily voids from baseline in subjects with at least 8 voids at baseline. | 6 and 12 months | |
| Secondary | Phase II Comprehensive Summary of all Adverse Events | The incidence of adverse events will be reported. | 6 and 12 months | |
| Secondary | Phase II Device Parameter Information Collected | Device amplitude will be collected in volts. | 6 and 12 months | |
| Secondary | Phase II Physician and Subject User Experience Questionnaire | Physician and subject satisfaction will be obtained by answering questions on the use of the device using a five point scale:strongly agree, agree, neither agree nor disagree, disagree, strongly disagree. Answers towards strongly agree indicate a better outcome. | 6 and 12 months | |
| Secondary | Phase II Urinary Tract Symptoms Questionnaire: International Consultation on Incontinence Questionnaire Female & Male Lower Urinary Tract Symptoms Modules | Change in male/female lower urinary tract symptoms questionnaire. Male questionnaire score ranges from 0-52 and female questionnaire score ranges from 0-48. Higher number indicates worse outcome. | 6 and 12 months | |
| Secondary | Phase II Safety Endpoint: Defined as the incidence of device-related serious adverse events in the post-trial period follow-up. | The number of serious adverse events related to the device. | 12 months | |
| Secondary | Phase II Urinary Output | Total urinary output as measured by 72-hour bladder diary. | 6 and 12 months | |
| Secondary | Phase II Fecal Incontinence Measured by Wexner Scale | Fecal incontinence as measured by the Wexner Scale compared to baseline. Wexner scale total points 0-20, higher the score the worse the outcome. | 6 and 12 months | |
| Secondary | Phase II Patient Global Impression of Improvement | Patient Global Impression of Improvement measured after implant during follow-up. Single question answered on a seven point scale: very much better, much better, a little better, no change, a little worse, much worse, very much worse. Selection of very much better is the best outcome. | 6 and 12 months |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01843543 -
Examining Bladder Control Using Mindful Based Approach
|
N/A |